Treatment patterns and health care costs for patients with psoriatic arthritis on biologic therapy: A retrospective cohort study

Clinical Therapeutics

Volumn 35, Issue 9, 2013, Pages 1376-1385

  Zhu, Baojin ^a   Edson Heredia, Emily ^a   Gatz, Jennifer L ^b   Guo, Jiaying ^c   Shuler, Catherine L ^a  

^a ELI LILLY AND COMPANY   (United States)

^b REGENSTRIEF INSTITUTE   (United States)

^c SYNEOS HEALTH   (United States)

Author keywords

Biologics; Disease modifying anti rheumatic drugs; Medical expenditures; Psoriatic arthritis; Treatment patterns

Indexed keywords

ANTIDEPRESSANT AGENT; ANTIHYPERTENSIVE AGENT; DISEASE MODIFYING ANTIRHEUMATIC DRUG; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPNOTIC AGENT;

ADULT; ARTICLE; BIOLOGICAL THERAPY; CHARLSON COMORBIDITY INDEX; COHORT ANALYSIS; COMORBIDITY; DRUG USE; FEMALE; FOLLOW UP; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PSORIATIC ARTHRITIS; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS;

BIOLOGICS; DISEASE MODIFYING ANTI-RHEUMATIC DRUGS; MEDICAL EXPENDITURES; PSORIATIC ARTHRITIS; TREATMENT PATTERNS;

ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; BIOLOGICAL THERAPY; COHORT STUDIES; DATABASES, FACTUAL; DRUG COSTS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PATIENT COMPLIANCE; RETROSPECTIVE STUDIES;

EID: 84884349368     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2013.07.328     Document Type: Article

References (27)

1. Krueger G.C. Clinical features of psoriatic arthritis. Am J Manag Care 2002, 8(Suppl 6):S160-S170.
2. Gelfand J.M., Gladman D.D., Mease P.J., et al. Epidemiology of psoriatic arthritis in the population of the United States. J Am Acad Dermatol 2005, 53:573.e1-573.e13.
3. Naldi L., Mercuri S.R. Epidemiology of comorbidities in psoriasis. Dermatol Ther 2010, 23:114-118.
4. Neimann A.L., Porter S.B., Gelfand J.M. The epidemiology of psoriasis. Expert Rev Dermatol 2006, 1:63-75.
5. Husted J.A., Thavaneswaran A., Chandran V., et al. Cardiovascular and other comorbidities in patients with psoriatic arthritis: a comparison with patients with psoriasis. Arthritis Care Res (Hoboken) 2011, 63:1729-1735.
6. Rosen C.F., Mussani F., Chandran V., et al. Patients with psoriatic arthritis have worse quality of life than those with psoriasis alone. Rheumatology (Oxford) 2012, 51:571-576.
7. Fowler J.F., Duh M.S., Rovba L., et al. The impact of psoriasis on health care costs and patient work loss. J Am Acad Dermatol 2008, 59:772-780.
8. Schabert VF, Watson C, Gandra SR, et al. Annual costs of tumor necrosis factor inhibitors using real-world data in a commercially insured population in the United States. J Med Econ. 2011. Available at:. Accessed November 29, 2012. http://www.ncbi.nlm.nih.gov/pubmed/22115327.
9. Yu A.P. Economic burden of psoriasis compared to the general population and stratified by disease severity. Curr Med Res Opin 2009, 25:2429-2438.
10. Langham S., Langham J., Goertz H.-P., et al. Large-scale, prospective, observational studies in patients with psoriasis and psoriatic arthritis: A systematic and critical review. BMC Med Res Methodol 2011, 11:32.
11. Gottlieb A., Korman N.J., Gordon K.B., et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol 2008, 58:851-864.
12. Soriano E.R., McHugh N.J. Therapies for peripheral joint disease in psoriatic arthritis. A systematic review. J Rheumatol 2006, 33:1422-1430.
13. Ash Z., Gaujoux-Viala C., Gossec L., et al. A systematic literature review of drug therapies for the treatment of psoriatic arthritis: current evidence and meta-analysis informing the EULAR recommendations for the management of psoriatic arthritis. Ann Rheum Dis 2012, 71:319-326.
14. Soriano E.R. The Actual Role of Therapy with Traditional Disease-modifying Antirheumatic Drugs in Psoriatic Arthritis. J Rheumatol Suppl 2012, 89:67-70.
15. Kavanaugh A.F., Ritchlin C.T. Systematic review of treatments for psoriatic arthritis: an evidence based approach and basis for treatment guidelines. J Rheumatol 2006, 33:1417-1421.
16. Olivieri I., de Portu S., Salvarani C., et al. PACE working group. The psoriatic arthritis cost evaluation study: a cost-of-illness study on tumour necrosis factor inhibitors in psoriatic arthritis patients with inadequate response to conventional therapy. Rheumatology (Oxf) 2008, 47:1664-1670. Epub 2008 Aug 24.
17. Deyo R.A., Cherkin D.C., Ciol M.A. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992, 45:613-619.
18. Calin A., Dijkmans B., Emery P., et al. Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis. Ann Rheum Dis 2004, 63:1594-1600.
19. Keystone E.C., Kavanaugh A.F., Sharp J.T., et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum 2004, 50:1400-1411.
20. Smolen J.S., Emery P. Infliximab: 12 years of experience. Arthritis Res Ther 2011, 13(Suppl 1):S2.
21. Nakamae T., Ochi M., Olmarker K. Pharmacological inhibition of tumor necrosis factor may reduce pain behavior changes induced by experimental disc puncture in the rat: an experimental study in rats. Spine 2011, 36:E232-E236.
22. Wu J.J., Poon K.-Y.T., Channual J.C., et al. Association Between Tumor Necrosis Factor Inhibitor Therapy and Myocardial Infarction Risk in Patients With Psoriasis. Arch Dermatol 2012, 148:1248-1250.
23. Chastek B., Fox K.M., Watson C., et al. Etanercept and adalimumab treatment patterns in psoriatic arthritis patients enrolled in a commercial health plan. Adv Ther 2012, 29:691-697.
24. Rubbert-Roth A., Finckh A. Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: a critical review. Arthritis Res Ther 2009, 11(Suppl 1):S1.
25. Cantini F., Niccoli L., Nannini C., et al. Frequency and duration of clinical remission in patients with peripheral psoriatic arthritis requiring second-line drugs. Rheumatology (Oxford) 2008, 47:872-876. Epub 2008 Apr 9.
26. Krieckaert C.L.M., Bartelds G.M., Lems W.F., et al. The effect of immunomodulators on the immunogenicity of TNF-blocking therapeutic monoclonal antibodies: a review. Arthritis Res Ther 2010, 12:217.
27. Bonafede M.M.K., Gandra S.R., Watson C., et al. Cost per treated patient for etanercept, adalimumab, and infliximab across adult indications: a claims analysis. Adv Ther 2012, 29:234-248.